24 February 2021 - Kura Oncology today announced that its investigational drug, tipifarnib, has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. 

Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial in this indication of high unmet need.

Read Kura Oncology press release